Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50

Vericel Corporation (NASDAQ:VCEL) is one of the best small cap stocks to buy with huge upside potential. Truist analyst Richard Newitter slashed the price target on Vericel Corporation (NASDAQ:VCEL) to $45 from $50 on December 18, reaffirming a Buy rating on the stock as part of a broader research note previewing the coming year for the MedTech sector. Similarly, on December 16, Canaccord Genuity reaffirmed a Buy rating on Vericel Corporation (NASDAQ:VCEL) and set a $58 price target.

Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling

In its fiscal Q3 2025 results, Vericel Corporation (NASDAQ:VCEL) reported that the total net revenue for the quarter rose to $67.5 million compared to $57.9 million in the prior year period, while total net product revenue included $55.7 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue compared to $44.7 million in the prior year period, and $10.4 million of Epicel (cultured epidermal autografts) net revenue compared to $44.7 million. It also included $1.5 million of NexoBrid (anacaulase-bcdb) net revenue, down from  $1.1 million in fiscal Q3 2024.

Vericel Corporation (NASDAQ:VCEL) further reported that the total operating expenses for the quarter rose to $46.1 million compared to $44.1 million for the same period in 2024, with the increase primarily attributed to the rise in headcount and related employee expenses, along with additional costs related to the company’s new Burlington facility, including depreciation and MACI tech transfer activities.

Vericel Corporation (NASDAQ:VCEL) has a total full-year revenue guidance of $272 to $276 million, and reaffirmed its MACI full-year revenue growth in the low 20% range, or $237.5 to $239.5 million. The company also reaffirmed full-year profitability guidance of 74% gross margin and adjusted EBITDA margin of 26%.

Vericel Corporation (NASDAQ:VCEL) is involved in product development, research, manufacturing, and distribution of patient-specific, expanded cellular therapies that help treat diseases. The company’s product portfolio includes Epicel and MACI. Epicel covers skin replacement for patients with deep dermal or full-thickness burns, while the MACI portfolio is FDA-approved for the process of tissue engineering for cell growth on scaffolds using healthy cartilage tissue derived from the patient’s own knee.

While we acknowledge the potential of VCEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VCEL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.